PMI 002

Drug Profile

PMI 002

Alternative Names: PMI-002

Latest Information Update: 21 Aug 2009

Price : $50

At a glance

  • Originator Phytomedics
  • Class Antineoplastics; Phytotherapies
  • Mechanism of Action Apoptosis stimulants; JNK mitogen-activated protein kinase inhibitors; Multidrug resistance-associated protein 1 inhibitors; P-glycoprotein inhibitors; Phosphotransferase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 21 Aug 2009 Preclinical development is ongoing in USA
  • 24 Oct 2003 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top